Abzena, a contract manufacturer of biologics and antibody drug conjugates, has entered into a master services agreement with an undisclosed US biotechnology company to provide process development and manufacturing services to progress an antibody-drug conjugate (ADC) towards clinical trials.

Abzena says the value of the entire process development and GMP manufacturing services exceeds $5 million, with the majority of the services to be provided within the next 12 months. The services will be carried out principally by Abzena’s chemistry and biomanufacturing groups in Bristol, Pennsylvania and San Diego, California.

Abzena has worked with the US-based company for years, with the relationship built around Abzena’s chemistry services. Following the initial chemistry development, Abzena subsequently developed a cell line that will now be used to produce the antibody at its GMP manufacturing facility. Abzena also plans to conduct GMP production of the ADC payload reagent and the conjugation process to create the ADC for initial clinical study.

Source: Abzena